Pharmaceutical sector mainstay Gilead Sciences (GILD -10.15%) has had many good days on the stock exchange, but Monday wasn't one of them. On the back of dispiriting clinical trial results for one of its investigational medications, investors sent the company's share price down by more than 10%. And that was on a day when the bellwether S&P 500 index ended in positive territory, rising almost 0.3%.Trodelvy didn't meet its latest primary endpointThat trial was a late-stage one for Trodelvy, an approved cance ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial.The results are a blow to Gilead, which is working to become a power player in the cancer space. The treatment, Trodelvy, is one of Gilead's best-selling cancer drugs, contributing roughly a third of its $769 million in oncology sales during the third quarter.The phase-three study is part of an effort to expand the use of Trodelvy, ...

Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.Trodelvy failed to meet primary endpointCopy link to sectionTrodelvy did not meet the “primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer”. EVOKE-01 – the aforementioned phase three trial evaluated the drug conjugate versus docetaxel, as per a press release on Monday.The news arrives only days befor ...

Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it plunged 14.3% on Dec. 22, 2014. The company said the Phase 3 Evoke-01 study of Trodelvy vs. docetaxel did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung ...

Gilead Sciences (GILD) closed at $86.48 in the latest trading session, marking a +0.57% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.56%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.59%.Shares of the HIV and hepatitis C drugmaker witnessed a gain of 8.18% over the previous month, beating the performance of the Medical sector with its gain of 3.8% and the S&P 500's gain of 1.2%.Analysts and investors alike will be keeping a close eye ...

In a downtown Toronto skyscraper one block away from the Hockey Hall of Fame, a small hedge fund is hoping it has found an edge in financial markets. Castle Ridge Asset Management is betting on Wallace, a purpose-built supercomputer behind the hedge fund’s trading strategies driven by artificial intelligence.For years, hedge-fund players have wondered if AI could help them beat the market, but AI-trading efforts they launched often led to disappointment and amounted to little more than marketing schemes to ...

The latest trading session saw Gilead Sciences (GILD) ending at $85.39, denoting a +1.05% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.07% for the day.Shares of the HIV and hepatitis C drugmaker witnessed a gain of 1.7% over the previous month, trailing the performance of the Medical sector with its gain of 7.37% and the S&P 500's gain of 3.98%.Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. ...

GILD crossed a key level to end 2023, and could be set up for more gains in 2024Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024. For today, we have pharma stock Gilead Sciences, Inc. (NASDAQ:GILD). To access the entirety of the 2024 report, click here.The shares of pharma giant Gilead Sciences (GILD) broke out of a major basing pattern back in late 2022, which had begun forming in 2017. The equity also crossed above the round-number $100 billion market c ...

Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn’t a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024. Gilead Sciences is doing important scientific work, and the company’s financials are fairly solid. Sure, weight-loss products deserve attention, but analysts and investors seem to be obsessing over them lately. Meanwhile, Gilead Sciences is making headway with critical, potentially lifesaving treatments. So, if you like ...